Answers are grounded in this paper and cite their sources.
Clinical analysis demonstrates reduced fat-free mass alongside weight loss in type 2 diabetes mellitus, highlighting the need to monitor muscle loss.
Although semaglutide, dapaglifrozin, and canagliflozin have a large weight loss effect, it is important to pay attention to muscle loss because a decrease in FFM was observed.
No takes yet. Share an insight, caveat, or question.
Ida et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: